Healthcare Industry News: Ranbaxy Laboratories
News Release - May 29, 2007
Pfizer Will Immediately Seek to Appeal Lipitor Patent Ruling in NorwayDecision has no bearing on Lipitor patent challenges in other countries
NEW YORK--(HSMN NewsFeed)--Pfizer Inc. said today that it will immediately seek to appeal a ruling by the Borgarting Court of Appeal in Oslo, Norway that four of Pfizer's patents covering Lipitor are either invalid or not infringed by a proposed generic atorvastatin calcium product from Ranbaxy Laboratories. The Supreme Court of Norway will determine whether to hear the appeal.
"We are disappointed by the court's ruling," said Pfizer's Senior Vice President and General Counsel Allen Waxman. "But we are confident that, if the Supreme Court agrees to hear our appeal, we will be able to make a compelling argument in support of our patents." Waxman pointed out that this ruling has no bearing on Lipitor patent challenges pending in other countries, including the United States.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.